Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers

Core Viewpoint - Novo Nordisk has issued a statement regarding Hims & Hers' illegal mass-marketing of an unapproved and untested semaglutide pill, emphasizing the risks to patient safety and the need for legal action to protect its intellectual property and the integrity of the drug approval framework [1][2]. Group 1: Legal and Regulatory Actions - Hims & Hers' actions are described as illegal mass compounding, which poses significant risks to patient safety [2]. - Novo Nordisk plans to take legal and regulatory action to safeguard patients and its intellectual property [2]. Group 2: Industry Standards and Safety Concerns - The American Diabetes Association®'s Obesity Association™ has published new standards discouraging the use of compounded GLP-1s due to concerns over safety, quality, and effectiveness [3]. - Compounded semaglutide is not FDA-approved and may contain impurities and untested doses, raising safety concerns [4]. Group 3: Product Information - Only Novo Nordisk manufactures the FDA-approved Wegovy® pill, which utilizes SNAC technology for oral semaglutide absorption [4]. - Wegovy® is available in all doses and is in full supply across the US [4].